Allist(SH:688578)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥366,401,012.10, representing an increase of 421.15% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2021 was ¥213,249,396.43, with a year-to-date net profit of ¥134,907,629.99, reflecting significant growth[5]. - The basic earnings per share for Q3 2021 was ¥0.47, compared to ¥0.30 year-to-date last year[5]. - The total profit for Q3 2021 was CNY 134,907,629.99, a significant recovery from a loss of CNY -204,843,004.37 in the same period last year[27]. - Basic and diluted earnings per share for Q3 2021 were both CNY 0.30, compared to a loss of CNY -0.57 per share in Q3 2020[28]. - The net profit for the first three quarters of 2021 was CNY 134.37 million, a recovery from a loss of CNY 204.83 million in the same period of 2020[26]. Research and Development - R&D investment totaled ¥70,734,285.83 in Q3 2021, an increase of 70.98% year-over-year, accounting for 19.31% of operating revenue[5]. - The company is focused on continuous research and development to enhance its product pipeline and address unmet medical needs in oncology[19]. - Research and development expenses for the first three quarters of 2021 were CNY 163.36 million, up from CNY 136.60 million in 2020, indicating a growth of about 19.5%[26]. Market Expansion and Product Development - The company confirmed that the significant increase in revenue was primarily due to the domestic launch of Fumetin in March 2021 and related overseas licensing income[10]. - The core product, Vomeletin, has expanded its coverage in commercial insurance, now included in over 20 provinces or cities in China, benefiting more lung cancer patients[18]. - The company is actively expanding its market presence through new product launches and clinical trials, enhancing its competitive position in the pharmaceutical industry[18]. - The company has established partnerships for overseas licensing, contributing to its revenue growth from international markets[18]. - The company plans to continue expanding its market presence and investing in R&D to support future growth initiatives[10]. Clinical Trials and Product Efficacy - The Phase III clinical trial for Vomeletin in treating EGFR-sensitive mutations has met its primary endpoint for progression-free survival (PFS), showing significant clinical benefits compared to the control group[19]. - Vomeletin's clinical data for treating EGFR 20 exon insertion mutations was presented at the 2021 ESMO, demonstrating a 60% objective response rate (ORR) and a 100% disease control rate (DCR) in the study population[20]. - The company has not reported any grade 3 or higher treatment-emergent adverse events (TEAEs) during the trials, indicating a favorable safety profile for Vomeletin[20]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥89,654,449.26, reflecting strong cash generation from sales[5]. - Cash flow from operating activities for the first nine months of 2021 was CNY 89,654,449.26, a turnaround from a negative cash flow of CNY -145,488,746.13 in the same period last year[30]. - The company reported a significant increase in cash and cash equivalents, totaling CNY 965.23 million as of September 30, 2021, compared to CNY 365.84 million at the end of 2020, representing a growth of approximately 164.5%[24]. - The ending balance of cash and cash equivalents as of Q3 2021 was CNY 965,234,645.72, up from CNY 169,672,791.84 in the same period last year[31]. Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥3,171,611,156.60, a 6.18% increase from the end of the previous year[5]. - The total current assets amounted to CNY 2.71 billion, slightly up from CNY 2.68 billion, indicating a growth of approximately 1.5%[24]. - The company’s total liabilities decreased to CNY 102.13 million from CNY 109.01 million, showing a reduction of about 6.5%[25]. - The equity attributable to shareholders increased to CNY 3.07 billion from CNY 2.88 billion, reflecting a growth of approximately 6.6%[25]. - The total liabilities amounted to ¥109,166,586.17, showing a slight increase due to adjustments in estimated liabilities[35].